Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Compelling article today from SeekingAlpha:
http://seekingalpha.com/article/2996506-neostems-one-year-trial-results-could-bounce-shares?auth_param=2era9:1ag3mlk:c1bf74adaa9bdc53d004b7386cb0ad70&uprof=45
WS
Stem cells and heart muscle restoration in Spain:
http://news.yahoo.com/spain-uses-stem-cell-therapy-treat-damaged-hearts-005329488.html
ws
Holy Stem Cells, Batman!
$23 ??
http://seekingalpha.com/currents/post/1489021?source=email_rt_mc_readmore
WS
New SeekingAlpha article this morning:
http://seekingalpha.com/article/1859801-neostem-a-biotech-in-need-of-a-catalyst?source=email_rt_article_readmore
WS
SeekingAlpha Chipman article says "six reasons to buy":
http://seekingalpha.com/article/1845292-dynavax-technologies-6-reasons-to-buy?source=email_rt_article_readmore
WS
Insiders loading up on DVAX:
http://seekingalpha.com/article/1794622-insiders-are-buying-dynavax?source=yahoo
WS
SeekingAlpha article just out:
http://seekingalpha.com/currents/post/1297282?source=email_rt_mc_readmore
winesnob
Brian Nichols' interview with Dr. Pecora:
http://seekingalpha.com/article/1701302-neostem-understanding-research-and-its-implications-to-clinical-trials?source=email_rt_article_readmore
WS
The news is not all bad - just because someone else did not do things right, doesn't mean stem cells don't repair heart muscle. This just out from Brian Nichols at seekingalpha:
http://seekingalpha.com/article/1696712-neostem-continues-to-soar-behind-a-slew-of-key-developments?source=email_rt_article_readmore
WS
Wow, up another 9% today. This baby is going past the moon and on to the stars! And folks - don't expect a Baxter or GSK buyout, because way smart insiders have to know that the patents alone are worth minimum fifty bucks a share and so current owners will do a lot better by simply hanging on. And frankly, I don't even expect the need for another offering next year. So I am all in...
WS
Seeking Alpha article this am:
http://seekingalpha.com/article/1648602-neostem-a-three-pronged-catalyst-story?source=email_rt_article_readmore
WS
Yowza - jeez am I happy I backed up the truck to the NBS stock-loading dock last year! This stock will be $35 within a couple of years. Can you say "early retirement"?
http://seekingalpha.com/article/1604852-neostem-a-stem-cell-leader-making-all-the-right-moves?source=email_rt_article_readmore
WS
Brian Nichols has a new article just out:
http://seekingalpha.com/article/1584912-great-leadership-and-massive-opportunities-makes-this-hire-terrific?source=email_rt_article_readmore
WS
Where I come from 5x volume + 10% jump with no news = insider trading. These dweebs better be careful.
Not that I'm complaining - au contraire - I'm finally above water since I bought IMUC and looking forward to a nice happy additional runup.
People, this is not the time to bail or trade. The way to make money here is to think of it as an investment, rather than a flip - besides, do you want to pay 15% capgains or 33%? Doh. Anyway, NBS is still cheap - it's just that it's been discovered by a few wankers with sheckels. This is a keeper and if you try to trade in and out sooner or later you're going to be left at the station - it only takes one miss to get reamed. This company probably won't even be around long enough to do any more dilution - because it's going to be a snack for Glaxo or Pfizer or Amgen - at $28.
Now the real fun begins:
http://seekingalpha.com/article/1561952-neostem-announces-several-key-milestones-that-should-excite-investors?source=email_rt_article_title
Warning - some of the fun may be short covering....nawwwwww!
WS
Good news this morning for ImmunoCellular may be also good news for Neostem:
http://finance.yahoo.com/news/immunocellular-therapeutics-announces-recommendation-data-100000247.html
WS
Breaking - NBS in services agreement with Immunocellular (IMUC) to provide manufacturing servcies to support dendtritic cells vaccine R&D:
http://www.neostem.com/advisory/pct-and-immunocellular-therapeutics-target-cancer-with-dendritic-cell-vaccines.html
NeoStem's Subsidiary, PCT, Enters Into a Manufacturing Agreement With ImmunoCellular Therapeutics, Ltd. For Dendritic Cell Vaccines Targeting Brain and Other Cancers
Jun 3 2013
Allendale, N.J. and Los Angeles, Calif. -- NeoStem, Inc. (NYSE MKT:NBS), its subsidiary, Progenitor Cell Therapy LLC ("PCT"), and ImmunoCellular Therapeutics, Ltd. (NYSE MKT:IMUC) ("IMUC"), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today the execution of a Services Agreement under which PCT will provide cGMP ("current good manufacturing practices") manufacturing services to support research and development of IMUC's ICT-121 cell therapy product candidate, a dendritic cell vaccine targeting CD133 cells. PCT currently provides manufacturing services for IMUC's lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma, for its Phase II clinical trial.
"We are pleased with PCT's ability to scale up services, lower our cost of goods and provide high quality manufacturing to support our research and development activities," said Andrew Gengos, Chief Executive Officer of ImmunoCellular. "We look forward to continuing to work in partnership with PCT as we seek to advance our cancer vaccines through the clinical and regulatory process."
"We appreciate the opportunity to work with ImmunoCellular as a manufacturing partner. Our management is focused on growing the business through increased services and product offerings, including automation technologies geared toward improving efficiencies and lowering cost of goods," said Robert A. Preti, PhD, President and Chief Scientific Officer of PCT. "Whether through growing our client base or expanding or extending services with current clients, we see that the industry is taking notice of the process improvements and cost benefits of working with PCT."
"With its East and West Coast facilities, PCT has unique expertise in manufacturing, regulatory, logistical transport and commercialization for therapeutics development, and we are pleased that our clients have confidence in the quality and cost-effectiveness of our operations," said Robin L. Smith, M.D., MBA, Chairman and CEO of NeoStem. "We foresee meaningful client base growth as therapeutic development companies come to understand the critical importance of involving a skilled manufacturing partner and the cost-effectiveness of that partner possessing the ability to rapidly scale while providing excellent service."
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Patents abroad granted and rec:
http://seekingalpha.com/currents/post/1029141?source=email_rt_mc_readmore
WS
Strategic alliance - news this am -
http://finance.yahoo.com/news/neostems-subsidiary-progenitor-cell-therapy-113000569.html
WS
Folks, remember not to forget - sooner or later NBS is a probable acquisition play - bigger fish that want to get into stems, but don't have the R&D arm for it - much easier just to use the corporate kitty and buy off the shelf. Tender offer or stockswap valuations are almost always at a very nice premium to daily market cap...
eom,
WS
For those betting (waiting) for the bottom to come looking for you - sorry, but IMHO you just missed it. Yes, I will admit to some nervousness whilst I was backing up the truck to the loading dock for a huge haul of average-down - but then again, if every investment were that comfortable and certain, we'd all be hedge fund owners rather than wage slaves...
regards, WS
This is a long-term investment form me, not a series of day trades. I will be paying capital gains rates when I sell, not income rates! So I just backed up the truck to the loading dock and filled her nice and full, averaging down quite nicely, thank you very much! For those who plan to ride this gem up to ten bucks, you will be kicking yourself when we're back around $.75 and you were too chickensht to take advantage....so just do it!!
Article from Seeking Alpha this am:
http://seekingalpha.com/article/1357551-an-industry-outlook-with-analyst-vernon-bernardino?source=email_rt_article_readmore
If the foregoing weren't enough, here's even more fuel for the fire...wahooo...
http://seekingalpha.com/article/1262421-3-undiscovered-biotech-companies-for-the-healthcare-investor?source=yahoo
WS
FYI unless she had a recent sex-change op in the last few days of which I'm unaware - the CEO of NBS is [still] a woman - Robin Smith, MD.
You wouldn't by any chance have gotten her mixed up with Michael Corbett of Perritt Capital Management?
http://finance.yahoo.com/news/ceo-perritt-capital-management-appear-161043058.html
sheesh...
Just crossed the wires - breakout stocks:
http://www.stockpickr.com/3-stocks-under-5-making-big-moves.html-3?puc=yahoo&cm_ven=YAHOO
SW
Trader, I think it's in post # 1463:
CLSN THLD CTIX SBFM SNTA PCYC IMUC
Regards,
Scott
Ugly. Down all the way to $2.10 in after hours trading. Seems to have stabilized around $2.15:
http://quotes.freerealtime.com/dl/frt/M?IM=quotes&type=Time%26Sales&symbol=imuc
4:02PM ImmunoCellular Therapeutics Announces Proposed Public Offering of Common Stock and Warrants; size not disclosed (IMUC) 2.41 -0.06 : Co announced that it intends to offer shares of its common stock and warrants in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Lazard Capital Markets LLC is acting as sole book-running manager for the offering. While the offering is expected to price before 9:30 am EDT on October 18, 2012, the offering is subject to market conditions.
Got out completely last week with a sorry shrunken profit, but at least it wasn't a loss. The operative phrase above is "size not disclosed". That was a big mistake, IMO and contributed to a panic.
regards,
Scott
Hello IMUC folks,
FYI you can now listen to and view slides of Dr John Yu's presentation yesterday at:
http://www.veracast.com/webcasts/bio/investorforum2012/14212285.cfm
Registered individuals will need to log in; if not yet registered you will need to complete registration prior to logging in (registration is very simple). To view and advance the slides, place your cursor inside the marquee box which is in roughly the middle of the webpage, just above the word 'INVESTOR'. A picture of a magnifying glass will appear. Click on the magnifying glass to get started.
regards,
Scott